AKBA Akebia Therapeutics Inc.

7.73
-0.1  -1%
Previous Close 7.83
Open 7.82
Price To Book 1.97
Market Cap 919,429,514
Shares 118,943,016
Volume 772,848
Short Ratio
Av. Daily Volume 1,652,617
Stock charts supplied by TradingView

NewsSee all news

  1. Akebia Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that its President and Chief

  2. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted six newly-hired employees options to

  3. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 14 newly-hired employees options to

  4. Akebia Therapeutics to Present at Upcoming Investor Conferences

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives will

  5. Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results

    Funding expected to extend Company's cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat; MTPC's positive Phase 3 data show vadadustat's effect on hemoglobin

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2019.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
Phase 3 data due 2Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Akebia Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that its President and Chief

  2. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted six newly-hired employees options to

  3. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 14 newly-hired employees options to

  4. Akebia Therapeutics to Present at Upcoming Investor Conferences

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives will

  5. Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results

    Funding expected to extend Company's cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat; MTPC's positive Phase 3 data show vadadustat's effect on hemoglobin

  6. Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

    Each Study Met Primary Endpoint at 24-Weeks and Showed Vadadustat's Effect on Hemoglobin Was Sustained Through to 52-Weeks Data Presented at the American Society of Nephrology (ASN) Kidney Week 2019 by Mitsubishi

  7. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to

  8. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to

  9. Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

    INNO2VATE and PRO2TECT now fully enrolled; Company continues to expect to report top-line study results in Q2 of 2020 and mid-2020, respectively, subject to accrual of MACE Akebia Therapeutics, Inc. (NASDAQ:AKBA) today